Advertisement

Methylation Detection and Epigenomics in Pancreatic Cancer

  • Georg Feldmann
  • Anirban MaitraEmail author
Chapter

Abstract

Pancreatic cancer has both genetic and epigenetic underlying causes. The importance of epigenetic alterations in the formation and maintenance of malignant tumors has become apparent in the last decade, with accumulating evidence suggesting this is probably the most common clonal aberration in human neoplasia. Identifying epigenetic alterations in pancreatic cancer has not only enhanced our understanding of pancreatic cancer biology, but has also opened up avenues for the development of early detection and novel therapeutic strategies.

In this chapter, an overview of the current literature on epigenetic alterations found in pancreatic cancer is presented and discussed in the light of potential therapeutic applicability as well as pointing out possible future directions of studies combining global genetic and epigenetic analyses.

Keywords

Pancreatic Cancer Pancreatic Cancer Cell Promoter Hypermethylation Intraductal Papillary Mucinous Neoplasm Pancreatic Cancer Cell Line 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Abe T, Toyota M, Suzuki H et al (2005) Upregulation of BNIP3 by 5-aza-2′-deoxycytidine sensitizes pancreatic cancer cells to hypoxia-mediated cell death. J Gastroenterol 40:504–510PubMedCrossRefGoogle Scholar
  2. Aguirre AJ, Bardeesy N, Sinha M et al (2003) Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17:3112–3126PubMedCrossRefGoogle Scholar
  3. Aguirre AJ, Brennan C, Bailey G et al (2004) High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci USA 101:9067–9072PubMedCrossRefGoogle Scholar
  4. Akada M, Crnogorac-Jurcevic T, Lattimore S et al (2005) Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer. Clin Cancer Res 11:3094–3101PubMedCrossRefGoogle Scholar
  5. Ammerpohl O, Trauzold A, Schniewind B et al (2007) Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells. Br J Cancer 96:73–81PubMedCrossRefGoogle Scholar
  6. Aoki K, Yoshida T, Sugimura T et al (1995) Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res 55:3810–3816PubMedGoogle Scholar
  7. Arnold NB, Arkus N, Gunn J et al (2007) The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin Cancer Res 13:18–26PubMedCrossRefGoogle Scholar
  8. Babushok DV, Ostertag EM, Kazazian HH, Jr. (2007) Current topics in genome evolution: molecular mechanisms of new gene formation. Cell Mol Life Sci 64:542–554PubMedCrossRefGoogle Scholar
  9. Badal V, Chuang LS, Tan EH et al (2003) CpG methylation of human papillomavirus type 16 DNA in cervical cancer cell lines and in clinical specimens: genomic hypomethylation correlates with carcinogenic progression. J Virol 77:6227–6234PubMedCrossRefGoogle Scholar
  10. Bai J, Demirjian A, Sui J et al (2006) Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells. Biochem Biophys Res Commun 348:1245–1253PubMedCrossRefGoogle Scholar
  11. Bardeesy N, Aguirre AJ, Chu GC et al (2006) Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci USA 103:5947–5952PubMedCrossRefGoogle Scholar
  12. Bardeesy N, Sharpless NE (2006) RAS unplugged: negative feedback and oncogene-induced senescence. Cancer Cell 10:451–453PubMedCrossRefGoogle Scholar
  13. Bastian PJ, Palapattu GS, Lin X et al (2005) Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 11:4037–4043PubMedCrossRefGoogle Scholar
  14. Baylin SB, Fearon ER, Vogelstein B et al (1987) Hypermethylation of the 5′ region of the calcitonin gene is a property of human lymphoid and acute myeloid malignancies. Blood 70:412–417PubMedGoogle Scholar
  15. Berman DM, Karhadkar SS, Maitra A et al (2003) Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 425:846–851PubMedCrossRefGoogle Scholar
  16. Bird AP (1980) DNA methylation and the frequency of CpG in animal DNA. Nucleic Acids Res 8:1499–1504PubMedCrossRefGoogle Scholar
  17. Bird A (2002) DNA methylation patterns and epigenetic memory. Genes Dev 16:6–21PubMedCrossRefGoogle Scholar
  18. Boyes J, Byfield P, Nakatani Y et al (1998) Regulation of activity of the transcription factor GATA-1 by acetylation. Nature 396:594–598PubMedCrossRefGoogle Scholar
  19. Bracken AP, Pasini D, Capra M et al (2003) EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 22:5323–5335PubMedCrossRefGoogle Scholar
  20. Brummelkamp TR, Bernards R, Agami R (2002) Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2:243–247PubMedCrossRefGoogle Scholar
  21. Buyse IM, Shao G, Huang S (1995) The retinoblastoma protein binds to RIZ, a zinc-finger protein that shares an epitope with the adenovirus E1A protein. Proc Natl Acad Sci USA 92:4467–4471PubMedCrossRefGoogle Scholar
  22. Caldas C, Hahn SA, da Costa LT et al (1994) Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8:27–32PubMedCrossRefGoogle Scholar
  23. Caldas C, Kern SE (1995) K-ras mutation and pancreatic adenocarcinoma. Int J Pancreatol 18:1–6PubMedGoogle Scholar
  24. Chadwick RB, Jiang GL, Bennington GA et al (2000) Candidate tumor suppressor RIZ is frequently involved in colorectal carcinogenesis. Proc Natl Acad Sci USA 97:2662–2667PubMedCrossRefGoogle Scholar
  25. Chen RZ, Pettersson U, Beard C et al (1998) DNA hypomethylation leads to elevated mutation rates. Nature 395:89–93PubMedCrossRefGoogle Scholar
  26. Cho B, Lee H, Jeong S et al (2003) Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant stage of gastric carcinoma. Biochem Biophys Res Commun 307:52–63PubMedCrossRefGoogle Scholar
  27. Chuikov S, Kurash JK, Wilson JR et al (2004) Regulation of p53 activity through lysine methylation. Nature 432:353–360PubMedCrossRefGoogle Scholar
  28. Cooper DN, Gerber-Huber S (1985) DNA methylation and CpG suppression. Cell Differ 17:199–205PubMedCrossRefGoogle Scholar
  29. Coulondre C, Miller JH, Farabaugh PJ et al (1978) Molecular basis of base substitution hotspots in Escherichia coli. Nature 274:775–780PubMedCrossRefGoogle Scholar
  30. D'Alessio AC, Szyf M (2006) Epigenetic tete-a-tete: the bilateral relationship between chromatin modifications and DNA methylation. Biochem Cell Biol 84:463–476PubMedCrossRefGoogle Scholar
  31. de Bono JS, Kristeleit R, Tolcher A et al (2008) Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clin Cancer Res 14:6663–6673Google Scholar
  32. Deckert J, Struhl K (2001) Histone acetylation at promoters is differentially affected by specific activators and repressors. Mol Cell Biol 21:2726–2735PubMedCrossRefGoogle Scholar
  33. Dokmanovic M, Clarke C, Marks PA (2007) Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5:981–989PubMedCrossRefGoogle Scholar
  34. Eden A, Gaudet F, Waghmare A et al (2003) Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300:455PubMedCrossRefGoogle Scholar
  35. Ehrlich M, Woods CB, Yu MC et al (2006) Quantitative analysis of associations between DNA hypermethylation, hypomethylation, and DNMT RNA levels in ovarian tumors. Oncogene 25:2636–2645PubMedCrossRefGoogle Scholar
  36. Ehrlich M, Sanchez C, Shao C et al (2008) ICF, an immunodeficiency syndrome: DNA methyltransferase 3B involvement, chromosome anomalies, and gene dysregulation. Autoimmunity 41:253–271PubMedCrossRefGoogle Scholar
  37. Esteller M (2007) Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 16 Spec No 1:R50–59Google Scholar
  38. Fabbri M, Garzon R, Cimmino A et al (2007) MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 104:15805–15810PubMedCrossRefGoogle Scholar
  39. Feinberg AP, Vogelstein B (1983) Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301:89–92PubMedCrossRefGoogle Scholar
  40. Feldmann G, Maitra A (2008) Molecular genetics of pancreatic ductal adenocarcinomas and recent implications for translational efforts. J Mol Diagn 10:111–122PubMedCrossRefGoogle Scholar
  41. Feldmann G, Maitra A (2009) Molecular pathology of precursor lesions of pancreatic cancer: pancreatic intraepithelial neoplasia (PanIN), intraductal papillary mucinous neoplasm (IPMN) and mucinous cystic neoplasm (MCN). In: Neoptolemos JP et al (eds) Pancreatic Cancer. New York, SpringerGoogle Scholar
  42. Feldmann G, Beaty R, Hruban RH et al (2007a) Molecular genetics of pancreatic intraepithelial neoplasia. J Hepatobiliary Pancreat Surg 14:224–232CrossRefGoogle Scholar
  43. Feldmann G, Dhara S, Fendrich V et al (2007b) Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res 67:2187–2196CrossRefGoogle Scholar
  44. Feldmann G, Habbe N, Dhara S et al (2008) Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut 57:1420–1430PubMedCrossRefGoogle Scholar
  45. Fernandez-Zapico ME, Gonzalez-Paz NC, Weiss E et al (2005) Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. Cancer Cell 7:39–49PubMedCrossRefGoogle Scholar
  46. Foss CA, Fox JJ, Feldmann G et al (2007) Radiolabeled anti-claudin 4 and anti-prostate stem cell antigen: initial imaging in experimental models of pancreatic cancer. Mol Imaging 6:131–139PubMedGoogle Scholar
  47. Fraga MF, Ballestar E, Villar-Garea A et al (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37:391–400PubMedCrossRefGoogle Scholar
  48. Fu B, Guo M, Wang S et al (2007) Evaluation of GATA-4 and GATA-5 methylation profiles in human pancreatic cancers indicate promoter methylation patterns distinct from other human tumor types. Cancer Biol Ther 6:1546–1552PubMedCrossRefGoogle Scholar
  49. Fujiwara K, Fujimoto N, Tabata M et al (2005) Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res 11:1219–1225PubMedCrossRefGoogle Scholar
  50. Fukushima N, Sato N, Ueki T et al (2002) Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am J Pathol 160:1573–1581PubMedGoogle Scholar
  51. Fukushima N, Walter KM, Uek T et al (2003) Diagnosing pancreatic cancer using methylation specific PCR analysis of pancreatic juice. Cancer Biol Ther 2:78–83PubMedGoogle Scholar
  52. Gama-Sosa MA, Slagel VA, Trewyn RW et al (1983) The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res 11:6883–6894PubMedCrossRefGoogle Scholar
  53. Garcia-Cao M, O'Sullivan R, Peters AH et al (2004) Epigenetic regulation of telomere length in mammalian cells by the Suv39h1 and Suv39h2 histone methyltransferases. Nat Genet 36:94–99PubMedCrossRefGoogle Scholar
  54. Gardiner-Garden M, Frommer M (1987) CpG islands in vertebrate genomes. J Mol Biol 196:261–282PubMedCrossRefGoogle Scholar
  55. Gaudet F, Hodgson JG, Eden A et al (2003) Induction of tumors in mice by genomic hypomethylation. Science 300:489–492PubMedCrossRefGoogle Scholar
  56. Gibbons RJ (2005) Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes. Hum Mol Genet 14 Spec No 1:R85–R92Google Scholar
  57. Goessl C, Muller M, Miller K (2000) Methylation-specific PCR (MSP) for detection of tumour DNA in the blood plasma and serum of patients with prostate cancer. Prostate Cancer Prostatic Dis 3:S17Google Scholar
  58. Goggins M, Offerhaus GJ, Hilgers W et al (1998) Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am J Pathol 152:1501–1507PubMedGoogle Scholar
  59. Grady WM, Parkin RK, Mitchell PS et al (2008) Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer. Oncogene 27:3880–3888PubMedCrossRefGoogle Scholar
  60. Gray SG, Ekstrom TJ (2001) The human histone deacetylase family. Exp Cell Res 262:75–83PubMedCrossRefGoogle Scholar
  61. Greger V, Passarge E, Hopping W et al (1989) Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum Genet 83:155–158PubMedCrossRefGoogle Scholar
  62. Habbe N, Shi G, Meguid RA et al (2008) Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proc Natl Acad Sci USA 105:18913–18918PubMedCrossRefGoogle Scholar
  63. Haefner M, Bluethner T, Niederhagen M et al (2008) Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors. World J Gastroenterol 14:3681–3692PubMedCrossRefGoogle Scholar
  64. Hahn SA, Schutte M, Hoque AT et al (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271:350–353PubMedCrossRefGoogle Scholar
  65. Han H, Bearss DJ, Browne LW et al (2002) Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res 62:2890–2896PubMedGoogle Scholar
  66. Hingorani SR, Petricoin EF, Maitra A et al (2003) Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4:437–450PubMedCrossRefGoogle Scholar
  67. Hingorani SR, Wang L, Multani AS et al (2005) Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7:469–483PubMedCrossRefGoogle Scholar
  68. Hirano T, Shino Y, Saito T et al (2002) Dominant negative MEKK1 inhibits survival of pancreatic cancer cells. Oncogene 21:5923–5928PubMedCrossRefGoogle Scholar
  69. Hong SM, Kelly D, Griffith M et al (2008) Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas. Mod Pathol 21:1499–1507PubMedCrossRefGoogle Scholar
  70. Hoque MO, Topaloglu O, Begum S et al (2005) Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol 23:6569–6575PubMedCrossRefGoogle Scholar
  71. Hruban RH, Wilentz RE, Kern SE (2000) Genetic progression in the pancreatic ducts. Am J Pathol 156:1821–1825PubMedGoogle Scholar
  72. Hruban RH, Adsay NV, Albores-Saavedra J et al (2001) Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 25:579–586PubMedCrossRefGoogle Scholar
  73. Hruban RH, Takaori K, Klimstra DS et al (2004) An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 28:977–987PubMedCrossRefGoogle Scholar
  74. Hruban RH, Wilentz RE, Maitra A (2005) Identification and analysis of precursors to invasive pancreatic cancer. Methods Mol Med 103:1–13PubMedGoogle Scholar
  75. Hruban RH, Adsay NV, Albores-Saavedra J et al (2006) Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res 66:95–106PubMedCrossRefGoogle Scholar
  76. Hulst SLP (1905) Zur Kenntnis der Genese des Adenokarzinoms und Karzinoms des Pankreas. Virchows Arch 180:288–316CrossRefGoogle Scholar
  77. Hutchings IA, Tierney RJ, Kelly GL et al (2006) Methylation status of the Epstein-Barr virus (EBV) BamHI W latent cycle promoter and promoter activity: analysis with novel EBV-positive Burkitt and lymphoblastoid cell lines. J Virol 80:10700–10711PubMedCrossRefGoogle Scholar
  78. Iacobuzio-Donahue CA (2009) Epigenetic changes in cancer. Annu Rev Pathol 4:229–249Google Scholar
  79. Ionov Y, Nowak N, Perucho M et al (2004) Manipulation of nonsense mediated decay identifies gene mutations in colon cancer Cells with microsatellite instability. Oncogene 23:639–645PubMedCrossRefGoogle Scholar
  80. Ito K, Barnes PJ, Adcock IM (2000) Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol 20:6891–6903PubMedCrossRefGoogle Scholar
  81. Ivanov GS, Ivanova T, Kurash J et al (2007) Methylation-acetylation interplay activates p53 in response to DNA damage. Mol Cell Biol 27:6756–6769PubMedCrossRefGoogle Scholar
  82. Izumi H, Takahashi C, Oh J et al (2000) Tissue factor pathway inhibitor-2 suppresses the production of active matrix metalloproteinase-2 and is down-regulated in cells harboring activated ras oncogenes. FEBS Lett 481:31–36PubMedCrossRefGoogle Scholar
  83. Jaju RJ, Fidler C, Haas OA et al (2001) A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia. Blood 98:1264–1267Google Scholar
  84. Jansen M, Fukushima N, Rosty C et al (2002) Aberrant methylation of the 5′ CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanlNs. Cancer Biol Ther 1:293–296PubMedGoogle Scholar
  85. Jenuwein T (2006) The epigenetic magic of histone lysine methylation. FEBS J 273:3121–3135PubMedCrossRefGoogle Scholar
  86. Jiao L, Zhu J, Hassan MM et al (2007) K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking. Pancreas 34:55–62PubMedCrossRefGoogle Scholar
  87. Jin M, Udagawa K, Miyagi E et al (2001) Expression of serine proteinase inhibitor PP5/TFPI-2/MSPI decreases the invasive potential of human choriocarcinoma cells in vitro and in vivo. Gynecol Oncol 83:325–333PubMedCrossRefGoogle Scholar
  88. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415–428PubMedCrossRefGoogle Scholar
  89. Jones S, Zhang X, Parsons DW et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801–1806PubMedCrossRefGoogle Scholar
  90. Josse J, Kaiser AD, Kornberg A (1961) Enzymatic synthesis of deoxyribonucleic acid. VIII. Frequencies of nearest neighbor base sequences in deoxyribonucleic acid. J Biol Chem 236:864–875PubMedGoogle Scholar
  91. Kell J (2007) Drug evaluation: MGCD-0103, a histone deacetylase inhibitor for the treatment of cancer. Curr Opin Investig Drugs 8:485–492PubMedGoogle Scholar
  92. Khochbin S, Verdel A, Lemercier C et al (2001) Functional significance of histone deacetylase diversity. Curr Opin Genet Dev 11:162–166PubMedCrossRefGoogle Scholar
  93. Kim KC, Geng L, Huang S (2003a) Inactivation of a histone methyltransferase by mutations in human cancers. Cancer Res 63:7619–7623Google Scholar
  94. Kim SG, Wu TT, Lee JH et al (2003b) Comparison of epigenetic and genetic alterations in mucinous cystic neoplasm and serous microcystic adenoma of pancreas. Mod Pathol 16:1086–1094CrossRefGoogle Scholar
  95. Kim SJ, Kang HS, Chang HL et al (2008) Promoter hypomethylation of the N-acetyltransferase 1 gene in breast cancer. Oncol Rep 19:663–668PubMedGoogle Scholar
  96. Kirmizis A, Bartley SM, Farnham PJ (2003) Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy. Mol Cancer Ther 2:113–121PubMedGoogle Scholar
  97. Kleer CG, Cao Q, Varambally S et al (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100:11606–11611PubMedCrossRefGoogle Scholar
  98. Klose RJ, Bird AP (2006) Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci 31:89–97PubMedCrossRefGoogle Scholar
  99. Klose RJ, Zhang Y (2007) Regulation of histone methylation by demethylimination and demethylation. Nat Rev Mol Cell Biol 8:307–318PubMedCrossRefGoogle Scholar
  100. Koorstra JB, Hustinx SR, Offerhaus GJ et al (2008) Pancreatic carcinogenesis. Pancreatology 8:110–125PubMedCrossRefGoogle Scholar
  101. Kouskouti A, Scheer E, Staub A et al (2004) Gene-specific modulation of TAF10 function by SET9-mediated methylation. Mol Cell 14:175–182PubMedCrossRefGoogle Scholar
  102. Kouzarides T (2007) Chromatin modifications and their function. Cell 128:693–705PubMedCrossRefGoogle Scholar
  103. Lane TF, Sage EH (1994) The biology of SPARC, a protein that modulates cell-matrix interactions. FASEB J 8:163–173PubMedGoogle Scholar
  104. Leary RJ, Lin JC, Cummins J et al (2008) Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci USA 105:16224–16229PubMedCrossRefGoogle Scholar
  105. Lee MH, Reynisdottir I, Massague J (1995) Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 9:639–649PubMedCrossRefGoogle Scholar
  106. Lee TS, Kim JW, Kang GH et al (2006) DNA hypomethylation of CAGE promotors in squamous cell carcinoma of uterine cervix. Ann N Y Acad Sci 1091:218–224PubMedCrossRefGoogle Scholar
  107. Lee KH, Lotterman C, Karikari C et al (2009) Epigenetic silencing of microRNA miR-107 regulates cyclin-dependent kinase 6 (CDK6) expression in pancreatic cancer. Pancreatology 9:293–301PubMedCrossRefGoogle Scholar
  108. Lehmann U, Hasemeier B, Christgen M et al (2008) Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J Pathol 214:17–24CrossRefGoogle Scholar
  109. Lengauer C, Kinzler KW, Vogelstein B (1997) DNA methylation and genetic instability in colorectal cancer cells. Proc Natl Acad Sci USA 94:2545–2550PubMedCrossRefGoogle Scholar
  110. Li M, Bharadwaj U, Zhang R et al (2008) Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther 7:286–296PubMedCrossRefGoogle Scholar
  111. Luger K (2003) Structure and dynamic behavior of nucleosomes. Curr Opin Genet Dev 13:127–135PubMedCrossRefGoogle Scholar
  112. Lujambio A, Calin GA, Villanueva A et al (2008) A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA 105:13556–13561PubMedCrossRefGoogle Scholar
  113. Luo J, Li M, Tang Y et al (2004) Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc Natl Acad Sci USA 101:2259–2264PubMedCrossRefGoogle Scholar
  114. Maitra A, Hruban RH (2008) Pancreatic cancer. Annu Rev Pathol 3:157–188PubMedCrossRefGoogle Scholar
  115. Maitra A, Adsay NV, Argani P et al (2003) Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol 16:902–912PubMedCrossRefGoogle Scholar
  116. Margueron R, Trojer P, Reinberg D (2005) The key to development: interpreting the histone code? Curr Opin Genet Dev 15:163–176PubMedCrossRefGoogle Scholar
  117. Martin ST, Sato N, Dhara S et al (2005) Aberrant methylation of the Human Hedgehog interacting protein (HHIP) gene in pancreatic neoplasms. Cancer Biol Ther 4:728–733PubMedCrossRefGoogle Scholar
  118. Martinez-Balbas MA, Bauer UM, Nielsen SJ et al (2000) Regulation of E2F1 activity by acetylation. EMBO J 19:662–671PubMedCrossRefGoogle Scholar
  119. Matsubayashi H, Sato N, Brune K et al (2005) Age- and disease-related methylation of multiple genes in nonneoplastic duodenum and in duodenal juice. Clin Cancer Res 11:573–583PubMedGoogle Scholar
  120. Matsubayashi H, Canto M, Sato N et al (2006) DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. Cancer Res 66:1208–1217PubMedCrossRefGoogle Scholar
  121. Matsuoka S, Edwards MC, Bai C et al (1995) p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 9:650–662PubMedCrossRefGoogle Scholar
  122. McClelland M, Ivarie R (1982) Asymmetrical distribution of CpG in an 'average' mammalian gene. Nucleic Acids Res 10:7865–7877PubMedCrossRefGoogle Scholar
  123. Mok SC, Chan WY, Wong KK et al (1996) SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. Oncogene 12:1895–1901PubMedGoogle Scholar
  124. Moskaluk CA, Hruban RH, Kern SE (1997) p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 57:2140–2143PubMedGoogle Scholar
  125. Muraoka M, Konishi M, Kikuchi-Yanoshita R et al (1996) p300 gene alterations in colorectal and gastric carcinomas. Oncogene 12:1565–1569PubMedGoogle Scholar
  126. Nakata B, Wang YQ, Yashiro M et al (2002) Prognostic value of microsatellite instability in resectable pancreatic cancer. Clin Cancer Res 8:2536–2540PubMedGoogle Scholar
  127. Narayan A, Ji W, Zhang XY et al (1998) Hypomethylation of pericentromeric DNA in breast adenocarcinomas. Int J Cancer 77:833–838PubMedCrossRefGoogle Scholar
  128. Neureiter D, Zopf S, Leu T et al (2007) Apoptosis, proliferation and differentiation patterns are influenced by Zebularine and SAHA in pancreatic cancer models. Scand J Gastroenterol 42:103–116PubMedCrossRefGoogle Scholar
  129. Okami J, Simeone DM, Logsdon CD (2004) Silencing of the hypoxia-inducible cell death protein BNIP3 in pancreatic cancer. Cancer Res 64:5338–5346PubMedCrossRefGoogle Scholar
  130. Okano M, Bell DW, Haber DA et al (1999) DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99:247–257PubMedCrossRefGoogle Scholar
  131. Omura N, Goggins M (2009) Epigenetics and epigenetic alterations in pancreatic cancer. Int J Clin Exp Pathol 2:310–326PubMedGoogle Scholar
  132. Omura N, Li CP, Li A et al (2008) Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma. Cancer Biol Ther 7:1146–1156PubMedGoogle Scholar
  133. Ouaissi M, Sielezneff I, Silvestre R et al (2008) High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas. Ann Surg Oncol 15:2318–2328PubMedCrossRefGoogle Scholar
  134. Ougolkov AV, Bilim VN, Billadeau DD (2008) Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin Cancer Res 14:6790–6796PubMedCrossRefGoogle Scholar
  135. Parsi MA, Li A, Li CP et al (2008) DNA methylation alterations in endoscopic retrograde cholangiopancreatography brush samples of patients with suspected pancreaticobiliary disease. Clin Gastroenterol Hepatol 6:1270–1278PubMedCrossRefGoogle Scholar
  136. Perini G, Diolaiti D, Porro A et al (2005) In vivo transcriptional regulation of N-Myc target genes is controlled by E-box methylation. Proc Natl Acad Sci USA 102:12117–12122PubMedCrossRefGoogle Scholar
  137. Peters AH, O'Carroll D, Scherthan H et al (2001) Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell 107:323–337PubMedCrossRefGoogle Scholar
  138. Plath K, Fang J, Mlynarczyk-Evans SK et al (2003) Role of histone H3 lysine 27 methylation in X inactivation. Science 300:131–135PubMedCrossRefGoogle Scholar
  139. Pogribny IP, Basnakian AG, Miller BJ et al (1995) Breaks in genomic DNA and within the p53 gene are associated with hypomethylation in livers of folate/methyl-deficient rats. Cancer Res 55:1894–1901PubMedGoogle Scholar
  140. Qu G, Dubeau L, Narayan A et al (1999a) Satellite DNA hypomethylation vs. overall genomic hypomethylation in ovarian epithelial tumors of different malignant potential. Mutat Res 423:91–101Google Scholar
  141. Qu GZ, Grundy PE, Narayan A et al (1999b) Frequent hypomethylation in Wilms tumors of pericentromeric DNA in chromosomes 1 and 16. Cancer Genet Cytogenet 109:34–39CrossRefGoogle Scholar
  142. Robertson KD, Ait-Si-Ali S, Yokochi T et al (2000) DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet 25:338–342PubMedCrossRefGoogle Scholar
  143. Roelfsema JH, Peters DJ (2007) Rubinstein−Taybi syndrome: clinical and molecular overview. Expert Rev Mol Med 9:1–16PubMedCrossRefGoogle Scholar
  144. Ropero S, Fraga MF, Ballestar E et al (2006) A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet 38:566–569PubMedCrossRefGoogle Scholar
  145. Roth SY, Denu JM, Allis CD (2001) Histone acetyltransferases. Annu Rev Biochem 70:81–120PubMedCrossRefGoogle Scholar
  146. Sanders SL, Portoso M, Mata J et al (2004) Methylation of histone H4 lysine 20 controls recruitment of Crb2 to sites of DNA damage. Cell 119:603–614PubMedCrossRefGoogle Scholar
  147. Sato N, Goggins M (2006) The role of epigenetic alterations in pancreatic cancer. J Hepatobiliary Pancreat Surg 13:286–295PubMedCrossRefGoogle Scholar
  148. Sato N, Ueki T, Fukushima N et al (2002) Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology 123:365–372PubMedCrossRefGoogle Scholar
  149. Sato N, Fukushima N, Maehara N et al (2003a) SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 22:5021–5030CrossRefGoogle Scholar
  150. Sato N, Fukushima N, Maitra A et al (2003b) Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 63:3735–3742Google Scholar
  151. Sato N, Maitra A, Fukushima N et al (2003c) Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res 63:4158–4166Google Scholar
  152. Sato N, Fukushima N, Matsubayashi H et al (2004) Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling. Oncogene 23:1531–1538PubMedCrossRefGoogle Scholar
  153. Sato N, Matsubayashi H, Abe T et al (2005a) Epigenetic down-regulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling. Clin Cancer Res 11:4681–4688CrossRefGoogle Scholar
  154. Sato N, Matsubayashi H, Fukushima N et al (2005b) The chemokine receptor CXCR4 is regulated by DNA methylation in pancreatic cancer. Cancer Biol Ther 4:70–76CrossRefGoogle Scholar
  155. Sato N, Parker AR, Fukushima N et al (2005c) Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. Oncogene 24:850–858CrossRefGoogle Scholar
  156. Sato N, Fukushima N, Chang R et al (2006) Differential and epigenetic gene expression profiling identifies frequent disruption of the RELN pathway in pancreatic cancers. Gastroenterology 130:548–565PubMedCrossRefGoogle Scholar
  157. Sato M, Shames DS, Gazdar AF et al (2007) A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol 2:327–343PubMedCrossRefGoogle Scholar
  158. Sato N, Fukushima N, Hruban RH et al (2008) CpG island methylation profile of pancreatic intraepithelial neoplasia. Mod Pathol 21:238–244PubMedCrossRefGoogle Scholar
  159. Schultz C, Lemke N, Ge S et al (2002) Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo. Cancer Res 62:6270–6277PubMedGoogle Scholar
  160. Schutte M, Hruban RH, Hedrick L et al (1996) DPC4 gene in various tumor types. Cancer Res 56:2527–2530PubMedGoogle Scholar
  161. Schutte M, Hruban RH, Geradts J et al (1997) Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 57:3126–3130PubMedGoogle Scholar
  162. Shames DS, Minna JD, Gazdar AF (2007) DNA methylation in health, disease, and cancer. Curr Mol Med 7:85–102PubMedCrossRefGoogle Scholar
  163. Shi Y (2007) Histone lysine demethylases: emerging roles in development, physiology and disease. Nat Rev Genet 8:829–833PubMedCrossRefGoogle Scholar
  164. Shi Y, Lan F, Matson C et al (2004) Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119:941–953CrossRefGoogle Scholar
  165. Shiota K, Yanagimachi R (2002) Epigenetics by DNA methylation for development of normal and cloned animals. Differentiation 69:162–166PubMedCrossRefGoogle Scholar
  166. Sims RJ III, Millhouse S, Chen CF et al (2007) Recognition of trimethylated histone H3 lysine 4 facilitates the recruitment of transcription postinitiation factors and pre-mRNA splicing. Mol Cell 28:665–676PubMedCrossRefGoogle Scholar
  167. Sjoblom T, Jones S, Wood LD et al (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314:268–274PubMedCrossRefGoogle Scholar
  168. Skinner HG, Michaud DS, Giovannucci EL et al (2004) A prospective study of folate intake and the risk of pancreatic cancer in men and women. Am J Epidemiol 160:248–258PubMedCrossRefGoogle Scholar
  169. Smith TF, Waterman MS, Sadler JR (1983) Statistical characterization of nucleic acid sequence functional domains. Nucleic Acids Res 11:2205–2220PubMedCrossRefGoogle Scholar
  170. Steele-Perkins G, Fang W, Yang XH et al (2001) Tumor formation and inactivation of RIZ1, an Rb-binding member of a nuclear protein-methyltransferase superfamily. Genes Dev 15:2250–2262PubMedCrossRefGoogle Scholar
  171. Swartz MN, Trautner TA, Kornberg A (1962) Enzymatic synthesis of deoxyribonucleic acid. XI. Further studies on nearest neighbor base sequences in deoxyribonucleic acids. J Biol Chem 237:1961–1967PubMedGoogle Scholar
  172. Tabu K, Sasai K, Kimura T et al (2008) Promoter hypomethylation regulates CD133 expression in human gliomas. Cell Res 18:1037–1046PubMedCrossRefGoogle Scholar
  173. Tan SH, Ida H, Lau QC et al (2007) Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3. Oncol Rep 18:1225–1230PubMedGoogle Scholar
  174. Thayer SP, di Magliano MP, Heiser PW et al (2003) Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425:851–856PubMedCrossRefGoogle Scholar
  175. Ting AH, Jair KW, Suzuki H et al (2004) CpG island hypermethylation is maintained in human colorectal cancer cells after RNAi-mediated depletion of DNMT1. Nat Genet 36:582–584PubMedCrossRefGoogle Scholar
  176. Ting AH, Jair KW, Schuebel KE et al (2006a) Differential requirement for DNA methyltransferase 1 in maintaining human cancer cell gene promoter hypermethylation. Cancer Res 66:729–735CrossRefGoogle Scholar
  177. Ting AH, McGarvey KM, Baylin SB (2006b) The cancer epigenome-components and functional correlates. Genes Dev 20:3215–3231CrossRefGoogle Scholar
  178. Tokumaru Y, Nomoto S, Jeronimo C et al (2003) Biallelic inactivation of the RIZ1 gene in human gastric cancer. Oncogene 22:6954–6958PubMedCrossRefGoogle Scholar
  179. Tuck-Muller CM, Narayan A, Tsien F et al (2000) DNA hypomethylation and unusual chromosome instability in cell lines from ICF syndrome patients. Cytogenet Cell Genet 89:121–128PubMedCrossRefGoogle Scholar
  180. Tykocinski ML, Max EE (1984) CG dinucleotide clusters in MHC genes and in 5′ demethylated genes. Nucleic Acids Res 12:4385–4396PubMedCrossRefGoogle Scholar
  181. Ueki T, Toyota M, Sohn T et al (2000) Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res 60:1835–1839PubMedGoogle Scholar
  182. Ueki T, Toyota M, Skinner H et al (2001) Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma. Cancer Res 61:8540–8546PubMedGoogle Scholar
  183. van der Put NM, Gabreels F, Stevens EM et al (1998) A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 62:1044–1051Google Scholar
  184. Varambally S, Dhanasekaran SM, Zhou M et al (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624–629PubMedCrossRefGoogle Scholar
  185. Visser HP, Gunster MJ, Kluin-Nelemans HC et al (2001) The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol 112:950–958PubMedCrossRefGoogle Scholar
  186. Vogelstein B, Fearon ER, Hamilton SR et al (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319:525–532PubMedCrossRefGoogle Scholar
  187. Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10:789–799PubMedCrossRefGoogle Scholar
  188. Walsh CP, Bestor TH (1999) Cytosine methylation and mammalian development. Genes Dev 13:26–34PubMedCrossRefGoogle Scholar
  189. Wang GG, Allis CD, Chi P (2007) Chromatin remodeling and cancer, Part I: Covalent histone modifications. Trends Mol Med 13:363–372PubMedCrossRefGoogle Scholar
  190. Watanabe M, Ogawa Y, Itoh K et al (2008) Hypomethylation of CD30 CpG islands with aberrant JunB expression drives CD30 induction in Hodgkin lymphoma and anaplastic large cell lymphoma. Lab Invest 88:48–57PubMedCrossRefGoogle Scholar
  191. Wilentz RE, Geradts J, Maynard R et al (1998) Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. Cancer Res 58:4740–4744PubMedGoogle Scholar
  192. Wilentz RE, Goggins M, Redston M et al (2000) Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: A newly described and characterized entity. Am J Pathol 156:1641–1651PubMedGoogle Scholar
  193. Wood LD, Parsons DW, Jones S et al (2007) The genomic landscapes of human breast and colorectal cancers. Science 318:1108–1113PubMedCrossRefGoogle Scholar
  194. Yamada N, Hamada T, Goto M et al (2006) MUC2 expression is regulated by histone H3 modification and DNA methylation in pancreatic cancer. Int J Cancer 119:1850–1857PubMedCrossRefGoogle Scholar
  195. Yamamoto H, Itoh F, Nakamura H et al (2001) Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability. Cancer Res 61:3139–3144PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Pathology, The Sol Goldman Pancreatic Cancer Research CenterJohns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations